Sepsis is a leading healthcare problem, accounting for the vast majority of fatal events in critically ill patients.
Introduction
Sepsis, a life-threatening condition characterized by a systemic inflammatory state, accounts for a vast majority of fatal events in critically ill patients and thereby has an outmost impact in healthcare. In the US, where 750,000 sepsis and 250,000 deaths occur for this reason, the costs related to this systemic disorder are estimated at little < $ 17 billion/year. Severe sepsis, complicated by organ dysfunction or reduced blood supply, is associated with 30% -50% mortality, whereas mortality of septic shock is beyond 50%.
The incidence of sepsis is steadily increasing, and the burden of disease is expected to increase further due to the aging of the worldwide population and heightened comorbidities. A timely establishment of appropriate treatment is crucial for several critical conditions [ 1 ] .
The clinical presentation in adults can be hardly distinguishable from other non-infective conditions which share a systemic inflammatory response and are collectively named systemic inflammatory response syndrome (SIRS). There is striking contrast, however, in clinical similarity between sepsis and SIRS and the relative management, wherein the former condition requires antibiotic treatment, while the latter shows some contraindications for antibiotic treatment. There is no gold standard for the diagnosis of sepsis, the culture of a suspect fluid positive in one case out of three (at best) still remaining the gold standard. For these reasons, the discretional and appropriate use of some selected biomarkers may allow a faster diagnosis and better treatment for all patients.
For this proposal we considered not only biomarkers already standardized and actually used in clinical practice ( Table 1 ), but we also described those biomarkers which are still tested for experimental use.
Beyond early diagnosis and prompt treatment, both sepsis and SIRS require a multifaceted approach for monitoring the severity of the condition, risk of death and organ failure. Monitoring of the efficacy of therapeutic approach is also a major need in the emergency department (ED). The assessment of critically ill patient condition and prognosis is currently based on some scoring systems [e.g., the Sequential Organ Failure Assessment (SOFA) score], but with a flimsy relationship with the organ failure and prognosis in general. Sepsis and SIRS can trigger organ failure by different mechanisms, but, different organs might also heterogeneously influence different biomarkers [ 2 ] . This collective, opinion paper is aimed to provide an overview about the potential clinical usefulness of some biomarkers of sepsis in its diagnosis and prognosis, but also in the management of the disease. This manuscript represents a synopsis of the lectures on biomarkers and sepsis of the Third Italian GREAT Network Congress, which was held in Rome, 15 -19 October 2012 . We decided to use only the most relevant references for each biomarker as suggested by each participant at this consensus paper, since the aim of the manuscript was not to provide a systematic review but an opinion paper.
SIRS-Sepsis differential diagnosis: role for biomarkers
As shown in Table 2 the rapid diagnosis of sepsis in ED is often difficult since the symptoms are rather non-specific.
Among the 178 markers originally proposed in the review of Vincent [ 3 ] , only five of them showed both sensitivity and specificity above 90%. Among these, γ -interferon ( γ -IFN) inducible protein 10 (IP10) and Group IV phospholipase A2 type II (PLA 2 II) are poorly investigated in adult patients with sepsis. IP-10, a γ -IFN inducible cytokine, mediates T-cell and monocyte dependent events, and is characterized by angiostatic properties [ 4 ] . The secretory PLA 2 -IIA was mainly considered a proinflammatory enzyme, although its antibacterial properties raised the question as to whether its up-regulation during inflammation has to be considered detrimental. This negative effect has been recently reinforced, when it was shown that antisense PLA 2 RNA can reduce mortality in an experimental animal model of sepsis [ 5 ] . PLA 2 may hence represent a risk factor and be potentially useful also as prognostic marker and therapeutic target. IP-10, induced by IFN in T cell and monocyte-regulated inflammation, and PLA 2 -IIA, mainly stimulated by IL-6, TNF and IL-1, might therefore be used either separately or in combination for diagnosing sepsis. It is noteworthy, however, that a biomarker panel might hardly be considered sufficient to rule in or rule out sepsis. For this reason, a model integrating clinical and laboratory indicators is eagerly needed [ 6 ] . The plasma levels of IP-10 (p = 0.027) and PLA 2 (p < 0.01) were shown to be higher in patients with sepsis compared with those with non-infective SIRS, as it was for procalcitonin (p = 0.002). The predictive value of PLA 2 in diagnosing sepsis among SIRS patients was higher than for procalcitonin, while the results for IP-10 were worse than those of procalcitonin. In adults admitted in a medical ward, PLA 2 can thereby contribute to the diagnosis of sepsis among patients with SIRS, while the role of IP-10 is still debated.
Procalcitonin and diagnosis of infection in ED
The resistance to antibiotic and burden of infections due to multidrug-resistant bacteria represent a growing healthcare problem, in as much as nearly 25,000 patients die annually due to antibiotic resistance in Europe. More stringent efforts are thus urgently needed to reduce the empiric use of antimicrobial agents in non-bacterial diseases, as well as for shortening the duration of antibiotic treatment in bacterial infection with clinical resolution.
There is increasing interest in the use of innovative biomarkers such as procalcitonin (PCT). PCT is a 116 amino acid protein, precursor of calcitonin, physiologically produced by the C-cells of the thyroid. The transcription of the CALC-1 gene produces a 141-amino acid protein (preprocalcitonin), which comprises a signal sequence, the N-terminal region (N-PCT), the middle sequence of calcitonin, and the C-terminal region called ' katacalcin ' . Moreover, the alternative splicing of the gene can produce the α -calcitonin gene-related peptide, α -CGRP [ 7 ] .
Signs

SIRS criteria
Fever (usually) Temperature > 38 ° C or < 36 ° C Rapid breathing
Respiratory rate > 20/min or PCO 2 < 32 mm Hg Rapid heartbeat Heart rate > 90 bpm Increased white blood cell count White blood cell > 12,000/mm 3 or < 4000/mm 3 Table 2 Signs of sepsis in the emergency department.
It has been shown that the concentration of PCT is increased during septic conditions, and is correlated with the severity of microbial invasion. At present, this biomarker can be easily assessed in routine clinical practice, also as a stat test [ 8 ] . PCT can also be considered a relatively innovative and highly specific biomarker for the diagnosis of clinically relevant bacterial infections and sepsis, so that it is increasingly recognized as an important diagnostic tool in clinical practice [ 9 ] .
PCT assessment has been demonstrated to be useful in diagnosis of pneumonia in patients with shortness of breath [ 10 ] .
In several trials, the assessment of PCT for guiding initiation and length of antibiotic treatment in patients with acute respiratory infections was not associated with higher mortality rates or treatment failure, but significantly reduced the antibiotic consumption across different clinical settings [ 11 ] .
Based on these characteristics, PCT may be a safe and effective tool to guide clinical and therapeutic decision-making about antibiotic(s) administration, thus preventing unnecessary antibiotic use, reducing bacterial resistance and decreasing medical costs and drugrelated adverse events. The Swiss group of Sch ü etz and co-workers has proposed and tested a practical algorithm, wherein antibiotic treatment is driven by different concentrations of this biomarker ( Figure 1 ) . A simplified algorithm has also been proposed, based on only two levels of PCT (i.e., antibiotic therapy discouraged if PCT < 0.24 ng/mL and advisable when PCT > 0.25 ng/mL), but reliable trials are lacking. The appropriate interpretation of test results within the specific clinical setting, supported by validated clinical scoring tools, as well as accurate knowledge about the characteristics of the assay (e.g., use of highly sensitive PCT assays and adoption of appropriate threshold values) are essential requisites for a meaningful use of this marker [ 12 ] .
Neutrophil gelatinase-associated lipocalin (NGAL) and procalcitonin in the management of sepsis in ED
Acute kidney injury (AKI) during sepsis is due to the production of vasoconstrictor factors secondary to the alterations of the blood flow (activation of renin-angiotensin system), and also to the increase in reactive oxygen species production. Renal hypoperfusion, but also other mechanisms may influence the onset of AKI [ 13 ] .
The incidence of AKI in patients with severe sepsis ranges from 20% to 25% and the mortality is 70% [ 14 ] .
PCT is a well-known biomarker of both local infections and sepsis [ 15 ] , and is a prognostic factor for outcome in septic patients in the emergency setting [ 16 ] . As regards to the fast diagnosis of AKI in septic patients admitted to the ED, it is important to emphasize that the standard diagnostic factors (e.g., serum creatinine) are not able to rapidly recognize AKI because they rise slowly and reach a steady state when the process of AKI has already initiated [ 17 ] , so that there is a compelling need for faster and more specific biomarkers for early detection of AKI. The most promising of these is neutrophil gelatinase-associated lipocalin (NGAL), a lipocalin released by the neutrophils in response to bacterial components. It is also found in epithelial cells of all parenchimal organs of the body. In the kidney it is secreted by renal tubules and is one of most upregulated genes in the very acute phases of AKI [ 18 ] .
NGAL, especially when assessed in urine, is considered mainly a diagnostic biomarker of AKI [ 19 ] . Recently, plasma NGAL has been studied in the course of sepsis in intensive care unit (ICU) patients with and without AKI [ 20 ] . Interestingly, increased concentrations of this biomarker have been found in septic patients, especially in those with AKI, indicating that it is an expression of the worsening conditions of renal function during sepsis. Shapiro et al. have also demonstrated the usefulness of plasma NGAL in ED in predicting AKI in the first 72 h in septic patients but also in predicting adverse outcomes [ 21 ] .
A recent study also demonstrates the diagnostic role of PCT for sepsis and its importance in guiding antibiotic therapy [ 22 ] . In synthesis, plasma NGAL is increased in patients with sepsis, but its specific role in this condition is still controversial due to the potential confounding factor of extra-renal source of production [ 23 ] , especially leukocytes [ 24 ] . It should hence be considered as a complementary marker during the course of sepsis for the diagnosis of AKI, helping PCT to manage the septic process.
Multimarker approach to sepsis in the emergency room
In septic patients the early diagnosis and stratification of the severity is crucial, in order to start prompt and appropriate treatment in the ED [ 25 ] . Due to the complexity of septic response, it is unlikely that a single ideal biomarker will ever be found, whereas a combination of several tests may be more effective for diagnosis and management. A multimarker panel approach performed by rapid and accurate assays could be useful for emergency physicians to promptly identify sepsis thus managing to improve diagnosis, treatment and risk stratification. The most commonly known biomarkers showing a great diagnostic and prognostic value for sepsis are C reactive protein (CRP), PCT, Mid-regional pro-adrenomedullin (MR-proADM, Copeptin) and natriuretic peptides [ 26 ] .
A recent study [ 27 ] has shown that both MR-proADM and PCT may be helpful in the management of febrile patients in the ED. The aims of the study were to assess the prognostic value of MR-proADM and PCT in a cohort of well-defined febrile patients in the ED in comparison with the Acute Physiology And Chronic Health Evaluation (APACHE) II, and to evaluate the ability of both biomarkers to predict hospitalization of patients admitted to the ED with fever. One hundred and twenty-eight consecutive critically ill patients admitted to the ED were enrolled with fever and a suspicion of severe infection. A control group was considered for the comparison of PCT and MR-ProADM values between patients and the control group, assuming that high values of both molecules may be useful for diagnosing an infectious source. The results confirmed that both biomarkers have a prognostic role in a febrile patient population, as proven by the good correlation with the APACHE II score, particularly in patients with sepsis and septic shock. Moreover, the combined use of the two biomarkers can predict a subsequent hospitalization of febrile patients accessing the ED. The rational use of these two molecules, as a multimarker approach, could lead to several advantages, such as faster diagnosis, more accurate risk stratification, and optimization of treatment, with consequent benefit for the patients.
New biomarkers of sepsis
Among the new biomarkers recently proposed for diagnosis and severity stratification in severe sepsis and septic shock, thrombopoietin (TPO) has been the subject of enthusiastic investigation. TPO is a humoral growth factor mainly involved in regulation of platelet number and function [ 28 ] . Along with its actions on thrombopoiesis, TPO directly modulates the homeostatic potential of mature platelets by influencing their response to several stimuli. In particular, TPO enhances platelet aggregation in response to different agonists, an effect implicated in the pathogenesis of several human critical diseases, such as acute coronary syndrome [ 29 ] . Several studies have previously reported high circulating levels of TPO in adults and children with sepsis, as well as in normal volunteers after i.v. injection of bacterial endotoxins. Zakynthinos et al. also showed that TPO levels are significantly higher in severe sepsis and septic shock, and that sepsis severity is the major determinant of increased TPO levels in these patients [ 30 ] .
Recent data suggest an adjunctive role for TPO, as a pathogenic mediator of organ damage during septic shock. A correlation between TPO levels and platelet activation has been demonstrated in septic burned patients [ 31 ] , a phenomenon that may cause micro-thrombotic events and subsequent organ damage. Moreover, TPO is able to negatively modulate myocardial contractility by stimulating its receptor c-Mpl expressed on cardiomyocytes and the subsequent production of NO, and cooperates with TNF-α and IL-1 β in mediating the negative inotropic effect induced in vitro by serum of septic shock patients [ 32 ] .
Finally, preliminary data demonstrated that inhibition of biological activity of TPO by means of a chimeric fusion protein recently synthesized was effective to significantly reduce monocyte-platelet aggregation, as well as the development of organ damage, in two murine models of experimental sepsis. Elevated circulating TPO levels may hence be considered a marker of disease severity during sepsis and the inhibition of TPO biological activity in order to prevent organ failure in severe sepsis deserves further studies. Gas6 and protein S are ligands of TAM R. Gas6 was found to be similar to protein S, showing 44% amino acid identity and vitamin K-dependency. The vitamin K-dependent proteins share the Gla domain, containing several glutamic acids, which are γ -carboxylated in the endoplasmatic reticulum. The Gla domain enables Gas6 and protein S to bind surfaces containing negatively charged phospholipids, a mechanism involved in phagocytosis [ 33 ] .
Mutant mice that lack TAM R develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmunity, including rheumatoid arthritis, vasculitis and systemic lupus erythematosus (LES), resulting from the hyperactivation of antigen-presenting cells (APC) in which the three receptors are normally expressed. The chronic hyperactivation of APCs in the triple mutants indicates that signaling through the TAM R normally serves as a self-extinguishing regulatory mechanism that limits the severity and time course of inflammatory immune responses [ 34 ] .
Rapid clearance of apoptotic cells by macrophages is important to inhibit inflammation and autoimmune responses against intracellular antigens. Mer mutated mice were associated with macrophage deficient clearance of apoptotic thymocytes, which could be reversed in chimeric mice reconstituted with bone marrow from wildtype animals [ 35 ] .
In macrophages, only Mer is activated after Gas6 stimulation. In those cells it has been demonstrated that Gas6 inhibits TNF-α , IL-1 and IL-6 secretion after endotoxin challenge. Gas6, through activation of Mer, modulates macrophage cytokine secretion, triggering an ' anti-inflammatory pathway ' involving PI3K/Akt/GSK3 and NF-κB [ 36 ] .
Several receptors exist in soluble forms, consisting of the extracellular regions of the receptor. The soluble receptors can remove the ligand and thus inhibit signaling. In a mouse model of endotoxemia, activation of proteolysis gave rise to plasma levels of Mer (sMer), moreover recombinant sMer has been shown to inhibit phagocytosis in vitro [ 37 ] .
Plasma Gas6 levels increase in severe sepsis and in septic shock [ 38 , 39 ] . Plasma sAxl was found to be increased in patients with sepsis, severe sepsis and SIRS, however, while Gas6 showed 100% increase, sAxl levels were found only 20% higher over the controls [ 40 ] . In conclusion, several lines of evidence show that the plasma concentrations of both Gas6 and sAxl are increased in patients with infection as compared with controls. However, no significant differences were observed on plasma levels, for both, between septic shock plus severe sepsis and sepsis plus uncomplicated infection. On the contrary, sMer plasma levels have been found significantly increased in severe infection in respect of less severe infection and control groups, whereas STyro3 plasma levels were not.
Mature adrenomedullin: a new biomarker
Adrenomedullin (ADM) is a pluripotent peptide that plays a key role in vascular function. It is ubiquitously expressed with high expression in the adrenal medulla and vascular system. Plasma ADM is derived mainly from endothelial cells and its main function is vasodilation [ 41 ] .
The reliable measurement of mature ADM is hampered by the existence of a binding protein, the short half-life time of approximately 22 min (in vivo) [ 42 ] and the stickiness of the molecule, that binds non-specifically to surfaces due to its physico-chemical properties.
The stable prohormone fragment MR-proAMD was shown to be a strong prognosticator of death. In the Biomarkers in Acute Heart Failure (BACH) trial, MR-proADM was superior versus b-type natriuretic peptide (BNP) for predicting 90-day survival in patients presenting to the ED with dyspnea [ 43 ] .
In order to assess ADM dynamics for therapy monitoring it would be beneficial to measure the short half-lived mature ADM. The dynamics of the feedback regulated hormone could enable to reflecting treatment response.
A new assay was developed to reliably measure mature ADM. The performance was achieved by choice of anti-Cterminal and anti-mid-regional monoclonal antibodies. The addition of N-terminal ADM antibodies solves the problem of ' stickiness ' . Only by addition of the antibody, can calibrators be produced accurately and reproducibly. The assay requires a small sample volume of 50 μ L of plasma. The analyte stability in plasma was shown to be sufficient. Using the new ADM assay, ADM can be determined up to 3 (or 6) h with > 95% ( > 90%) recovery in plasma at room temperature. The ADM normal distribution has been determined by measurement of ADM values in 200 healthy subjects. The median ADM was shown to be 27.4 pg/mL. The analytical assay sensitivity was determined to be 2 pg/mL. Therefore, the new ultrasensitive ADM assay enables reliable quantification of even low ADM concentrations in healthy subjects. The new sandwich immunoassay for mature ADM is suitable for routine use and can serve as a tool to assess ADM dynamics in therapy monitoring.
Development of therapeutic antibodies directed to adrenomedullin: preclinical results from a resuscitated murine septic shock model
Sepsis leads to dysregulation of the endothelium, excessive vasodilation and consecutive collapse of blood pressure and microvascular homeostasis. The major function of ADM is vasodilation and subsequent regulation of the vascular tone [ 44 , 45 ] and it has been referred to as a ' double-edged sword ' during circulatory shock states. While genetic ADM overexpression or exo genous ADM supplementation improved organ function and survival [ 46 ] in experimental models due to maintenance of hyperdynamic hemodynamic in otherwise hypodynamic conditions, high blood levels were associated with increased mortality in patients with septic shock [ 47 ] , most likely as a result of excessive vasodilatation and/or impaired systolic heart function. The main disadvantage of the above-mentioned experimental models is the lack of adequate resuscitation therapy.
More than 30 monoclonal antibodies against human ADM by mouse have been developed and this screening led to successful identification of HAM1101, the H uman A dreno M edullin antibody. The impact of the new ADM antibody HAM1101 is under investigation in a model of fully resuscitated murine septic shock regarding the hypothesis that HAM1101 improves hemodynamics and reduces AKI. HAM1101 was successfully humanized to AdrenoMed ` s humanized monoclonal antibody drug candidate HAM8101. HAM8101 is currently in preclinical development of safety and toxicology studies as well as in drug substance production according GMP regulations. Clinical first-in-man studies are planned in the future.
Conclusions
Biomarkers may play an important role in the management of patients with sepsis in ED, since they could mirror presence, absence or severity of sepsis, and differentiate bacterial from viral and fungal infection, and systemic sepsis from local infection. Other potential uses of biomarkers include roles in risk stratification, guiding antibiotic therapy and evaluating the response to therapy. The combination of newer (adrenomedullin, sMer, thrombopoietin, NGAL) and ' older and well-known ' sepsis biomarkers such as PCT or red blood cell distribution width [ 48 ] , used as a multimarkers approach, may be useful for emergency physicians to promptly identify sepsis and improve diagnosis, identification of organ dysfunction, treatment and risk stratification.
Furthermore, targeting ADM with HAM1101 presents as a possible future therapy in septic shock, resulting in improved cardiovascular catecholamine responsiveness and attenuation of AKI. However, further studies comparing different biomarkers are needed.
